VTRS News and Press, Viatris Inc. From 07/14/23

2023-07-14 20:15:00 ET Summary The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. Looking back at my June totals, I see that my year-over-year progress ...

2023-07-14 07:45:00 ET Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof returns in all economic environments, this company is just at t...

2023-07-13 09:05:00 ET Healthcare stocks, particularly pharmaceutical stocks with solid dividends, make great long-term investments. In general, the need for healthcare products and services is stable, even during economic downturns. When high interest rates in early 2022 caused sev...

2023-07-07 03:12:00 ET Summary Rose's Income Garden portfolio saw 39 companies pay dividends in June, with seven raises and one cut; the portfolio yield is approximately 5.2% and its value increased by 1.75% YTD excluding dividends. The portfolio, which consists of 80 stocks from ...

2023-07-05 06:08:00 ET For a generic drugmaker like Viatris (NASDAQ: VTRS) , big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining strong cash flows that enable returning capital to investors. ...

2023-07-03 15:50:36 ET Summary FDA approval of Revance Therapeutics, Inc.'s DAXXIFY for glabellar lines in the U.S. achieved; Initial launch brought in revenues of $15.4 million. A supplemental Biologics Licensing Application of DAXXIFY for adults with cervical dystonia has been a...

2023-06-29 05:02:34 ET For further details see: Goldman adds 39 new stocks to its Sharpe Ratio basket with megacaps absent

NEW YORK, NY / ACCESSWIRE / June 28, 2023 / Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS) of a class action securities lawsuit. The lawsuit on behalf of Viatris investors has been commenced in the United States District Court for the W...

Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023 PR Newswire PITTSBURGH , June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open...

2023-06-23 09:50:46 ET Barclays downgraded Viatris Inc. ( NASDAQ: VTRS ) to Underweight from Equal Weight on Friday, noting that despite its low valuation, the generic drugmaker will likely remain a "show-me narrative" until there is clarity on its future strategy. The analyst B...